|
US4525359A
(en)
*
|
1982-12-10 |
1985-06-25 |
Greenway Frank L Iii |
Treatment for selective weight control
|
|
US5069911A
(en)
*
|
1985-02-05 |
1991-12-03 |
Sandoz Ltd. |
Pharmaceutical 9,10-dihydrogenated ergot alkaloid containing compositions
|
|
US5700800A
(en)
*
|
1988-05-10 |
1997-12-23 |
Ergo Science Incorporated |
Methods for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates with a prolactin stimulatory compound
|
|
US5668155A
(en)
*
|
1988-05-10 |
1997-09-16 |
The General Hospital Corporation |
Administration of pirenzepine, methyl scopolamine and other muscarinic receptor antagonists for treatment of lipid metabolism disorders
|
|
US5344832A
(en)
*
|
1990-01-10 |
1994-09-06 |
The Board Of Supervisors Of Louisiana University And Agricultural And Mechanical College |
Method for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hyperglycemia in vertebrates
|
|
US5468755A
(en)
*
|
1988-05-10 |
1995-11-21 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Therapeutic process for the treatment of the pathologies of Type II diabetes
|
|
US5585347A
(en)
*
|
1988-05-10 |
1996-12-17 |
Ergo Science Incorporated |
Methods for the determination and adjustment of prolactin daily rhythms
|
|
US6004972A
(en)
*
|
1988-05-10 |
1999-12-21 |
The Board Of Supervisiors Of Louisiana State University And Agricultural And Mechanical College |
Therapeutic process for the treatment of the pathologies of type II diabetes
|
|
US5830895A
(en)
*
|
1988-05-10 |
1998-11-03 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Methods for the determination and adjustment of prolactin daily rhythms
|
|
US5744477A
(en)
*
|
1988-05-10 |
1998-04-28 |
The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College |
Method for treatment of obesity using prolactin modulators and diet
|
|
US5006526A
(en)
*
|
1988-10-17 |
1991-04-09 |
Louisiana State University |
Method of treating a vertebrate animal to reduce plasma triglycerides and cholesterol levels and to alleviate and prevent atherosclerosis
|
|
CA2030174C
(en)
*
|
1990-01-10 |
1996-12-24 |
Anthony H. Cincotta |
Process for the long term reduction of body fat stores, insulin resistance, hyperinsulinemia and hypoglycemia in vertebrates
|
|
IL112106A0
(en)
*
|
1993-12-22 |
1995-03-15 |
Ergo Science Inc |
Accelerated release composition containing bromocriptine
|
|
US20010016582A1
(en)
|
1997-04-28 |
2001-08-23 |
Anthony H. Cincotta |
Method and composition for the treatment of lipid and glucose metabolism disorders
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
KR20040025890A
(ko)
*
|
2001-01-26 |
2004-03-26 |
쉐링 코포레이션 |
혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와 혈액조절제의 조합물
|
|
BR0206644A
(pt)
*
|
2001-01-26 |
2004-02-25 |
Schering Corp |
Combinações de inibidor(es) de absorção de esteróis com agente(s) cardiovascular(es) para o tratamento de condições vasculares
|
|
IL156445A0
(en)
*
|
2001-01-26 |
2004-01-04 |
Schering Corp |
Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
ATE369851T1
(de)
*
|
2001-01-26 |
2007-09-15 |
Schering Corp |
Kombinationen von gallensäuresequestriermitteln und hemmern der sterolabsorption zur behandlung von kardiovaskulären indikationen
|
|
SI1355644T1
(sl)
*
|
2001-01-26 |
2006-10-31 |
Schering Corp |
Uporaba substituiranih azetidinonskih spojin za zdravljenje sitosterolemije
|
|
TW200840563A
(en)
*
|
2001-01-26 |
2008-10-16 |
Schering Corp |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
|
|
US20030013699A1
(en)
*
|
2001-05-25 |
2003-01-16 |
Davis Harry R. |
Methods for treating alzheimer's disease and/or regulating levels of amyloid beta peptides in a subject
|
|
US7718802B2
(en)
|
2001-08-10 |
2010-05-18 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
|
US7456184B2
(en)
|
2003-05-01 |
2008-11-25 |
Palatin Technologies Inc. |
Melanocortin receptor-specific compounds
|
|
US7732451B2
(en)
|
2001-08-10 |
2010-06-08 |
Palatin Technologies, Inc. |
Naphthalene-containing melanocortin receptor-specific small molecule
|
|
US7354923B2
(en)
*
|
2001-08-10 |
2008-04-08 |
Palatin Technologies, Inc. |
Piperazine melanocortin-specific compounds
|
|
JP2005504043A
(ja)
*
|
2001-08-10 |
2005-02-10 |
パラチン テクノロジーズ インク． |
生物学的に活性な金属ペプチド類のペプチド模倣体類
|
|
US7655658B2
(en)
|
2001-08-10 |
2010-02-02 |
Palatin Technologies, Inc. |
Thieno [2,3-D]pyrimidine-2,4-dione melanocortin-specific compounds
|
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
DK1427409T3
(da)
*
|
2001-09-21 |
2009-01-12 |
Schering Corp |
Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
|
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
DK1429756T3
(da)
*
|
2001-09-21 |
2007-03-19 |
Schering Corp |
Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer
|
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
US20040092499A1
(en)
*
|
2002-11-06 |
2004-05-13 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of autoimmune disorders
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
WO2004081002A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
ATE418551T1
(de)
|
2003-03-07 |
2009-01-15 |
Schering Corp |
Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
|
|
CN1756755A
(zh)
*
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
US7968548B2
(en)
|
2003-05-01 |
2011-06-28 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine compounds with diamine groups
|
|
US7727990B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Melanocortin receptor-specific piperazine and keto-piperazine compounds
|
|
US7727991B2
(en)
|
2003-05-01 |
2010-06-01 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific single acyl piperazine compounds
|
|
WO2005046797A2
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
|
US7709484B1
(en)
|
2004-04-19 |
2010-05-04 |
Palatin Technologies, Inc. |
Substituted melanocortin receptor-specific piperazine compounds
|
|
US7834017B2
(en)
|
2006-08-11 |
2010-11-16 |
Palatin Technologies, Inc. |
Diamine-containing, tetra-substituted piperazine compounds having identical 1- and 4-substituents
|
|
EP2727587A1
(en)
*
|
2012-10-30 |
2014-05-07 |
Pharnext |
Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level
|